- Tytuł:
- Analgesic efficacy and safety of tapentadol in comparison with oxycodone in patients after open abdominal hysterectomy.
- Autorzy:
-
Kołodziej, Dorota
Szkutnik-Fiedler, Danuta
Bosacki, Ryszard
Michalak, Michał
Grześkowiak, Edmund
Szałek, Edyta - Powiązania:
- https://bibliotekanauki.pl/articles/895701.pdf
- Data publikacji:
- 2020-06-29
- Wydawca:
- Polskie Towarzystwo Farmaceutyczne
- Tematy:
-
Abdominal Hysterectomy
postoperative pain
oxycodone
tapentadol - Opis:
- Tapentadol is the newest opioid with dual mechanism of action, that gives the potential to spare some opioid-induced adverse events. Studies involving this drug in acute pain are not numerous. The aim of this study was to compare the efficacy and tolerance of tapentadol and oxycodone in patients after abdominal hysterectomy. Patients were randomly allocated into two groups receiving: I. tapentadol (50 mg) and II. oxycodone (10 mg), every 12 hours postoperatively. The Numerical Rating Scores (NRS), vital signs, main adverse events (postoperative nausea and vomiting, sedation) and other side effects would be recorded until discharge. Total opioid consumption, the patients’ satisfaction, adjuvants consumption, and length of hospital stay were also assessed Mean NRS scores for tapentadol and oxycodone after 24, 48 and 72 hours were: 3.43 (±1.29) vs 3.59 (±1.37), 2.87 (±1.07) vs 3.24 (±1.21), 2.80 (±1.05) vs 3.19 (±1.24), respectively. In the tapentadol group, superior pain control (p<0.05) in few time points during the day second was observed although demand for rescue analgesics was slightly higher (p>0.05). Mucosal dryness affected over >90% patients in both groups. The incidence of postoperative nausea was 39.5% (tapentadol) and 27% (oxycodone) on the first day. The incidence of drowsiness was 42.1% (tapentadol) and 37.8% (oxycodone). Other adverse events’ level, satisfaction with treatment, length of stay after surgery, effect on vital signs were comparable.
- Źródło:
-
Acta Poloniae Pharmaceutica - Drug Research; 2020, 77, 3; 505-514
0001-6837
2353-5288 - Pojawia się w:
- Acta Poloniae Pharmaceutica - Drug Research
- Dostawca treści:
- Biblioteka Nauki
Artykuł